Page last updated: 2024-08-23

paroxetine and Atrophy

paroxetine has been researched along with Atrophy in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crider, M; Hill, DA; Hill, SR1
Culp, S; DeSouza, EB; Lehmann, J; Zaczek, R1

Reviews

1 review(s) available for paroxetine and Atrophy

ArticleYear
Hormone Therapy and Other Treatments for Symptoms of Menopause.
    American family physician, 2016, Dec-01, Volume: 94, Issue:11

    Topics: Acupuncture Therapy; Administration, Intravaginal; Amines; Antidepressive Agents; Atrophy; Cyclohexanecarboxylic Acids; Dietary Supplements; Drug Therapy, Combination; Dyspareunia; Estrogen Replacement Therapy; Estrogens; Exercise Therapy; Female; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Humans; Hypnosis; Indoles; Menopause; Paroxetine; Progestins; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina; Vaginal Diseases; Vasomotor System; Venlafaxine Hydrochloride

2016

Other Studies

1 other study(ies) available for paroxetine and Atrophy

ArticleYear
Regional distribution to recovery of 5-HT levels after administration of "atrophins" MDMA and D,L-fenfluramine. Stereospecificity and comparison with 5,7-dihydroxytryptamine.
    Annals of the New York Academy of Sciences, 1992, May-11, Volume: 648

    Topics: 3,4-Dihydroxyphenylacetic Acid; 3,4-Methylenedioxyamphetamine; 5,7-Dihydroxytryptamine; Animals; Atrophy; Brain; Cerebral Ventricles; Designer Drugs; Dopamine; Fenfluramine; Homovanillic Acid; Hydroxyindoleacetic Acid; Injections, Intraventricular; Male; N-Methyl-3,4-methylenedioxyamphetamine; Norepinephrine; Organ Specificity; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Serotonin; Stereoisomerism

1992